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There is a very well known correlation between diabetes and cardiovascular disease but many health care
professionals are just concerned with glycemic control, ignoring the paramount importance of controlling other risk
factors involved in the pathogenesis of serious cardiovascular diseases. This Position Statement from the Brazilian
Diabetes Society was developed to promote increased awareness in relation to six crucial topics dealing with
diabetes and cardiovascular disease: Glicemic Control, Cardiovascular Risk Stratification and Screening Coronary
Artery Disease, Treatment of Dyslipidemia, Hypertension, Antiplatelet Therapy and Myocardial Revascularization. The
issue of what would be the best algorithm for the use of statins in diabetic patients received a special attention
and a new Brazilian algorithm was developed by our editorial committee. This document contains 38
recommendations which were classified by their levels of evidence (A, B, C and D). The Editorial Committee
included 22 specialists with recognized expertise in diabetes and cardiology.
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This Position Statement is a review based on the best
currently available scientific evidence to guide the pre-
vention and management of cardiovascular disease in
patients with diabetes. The document was developed by
endocrinologists and cardiologists gathered in the Group
of Experts on Diabetes and Cardiovascular Risk, which
contributed significantly to the development of this
document, formatted into practical recommendations
regarding management of cardiovascular disease in these
patients.
This paper innovates by reviewing the concept of
equivalence of cardiovascular risk in patients with dia-
betes in light of recent evidences suggesting the presence* Correspondence: pimazoni@uol.com.br
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unless otherwise stated.of lower-risk subgroups within this population. On the
other hand, targets of LDL-c on treatment with statins
are no longer recommended and the suggestion to make
therapeutic decisions based on the stratification of car-
diovascular risk by use of the calculator UKPDS cardio-
vascular risk assessment is now enforced.
Also incorporated, now in a more defined way, the use
of calcium score in more specific situations regarding
the use of statins. It was also included an update on the
recommendations for the treatment of hypertension, for
the use of antiplatelet and finally an update on indica-
tions for myocardial revascularization exclusively in pa-
tients with diabetes.
The Brazilian Diabetes Society (SBD= Sociedade Brasileira
de Diabetes) hopes that this review will be useful in cli-
nical practice targeting an increased quality of care for pa-
tients with diabetes.al Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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This Position Statement rated levels of evidence accor-
ding to Table 1, and for each recommendation, the evi-
dence is presented below.
Originally, the members of the editorial board defined
the topics considered relevant and that required posi-
tioning by SBD. Thereafter a search of the literature was
performed to select the most important studies. It was
then drafted a preliminary manuscript with the respec-
tive levels of evidence which underwent several rounds
of discussion among committee members for review and
suggestions. The manuscript then returned to the chief
editor for tweaking and unifying editorial style. The
manuscript was subsequently subjected to further revi-
sional rounds by some members of the committee in
seeking a consensus position and after this phase it was
forwarded for final editoring and then submitted for
publication.
Recommendations
The recommendations of this Position Statement of the
Brazilian Diabetes Society will be divided into six mo-
dules, namely:
– Module 1: Glicemic Control
– Module 2: Cardiovascular Risk Stratification and
Coronary Disease Screening
– Module 3: Treatment of Dyslipidemia
– Module 4: Treatment of Hypertension
– Module 5: Antiplatelet Therapy
– Módulo 6: Myocardial Revascularization
– References
The numbered references in the texts of each module
are described at the end of the full text.
Module 1: glycemic control
1. In adult patients with diabetes mellitus, target
HbA1c of approximately 7.0% is recommended.
[Level A]Table 1 Levels and descriptions of evidence
Levels of evidence Description
Level A
Direct evidence from meta-analysis or
randomized clinical trials
Level B
Evidence from large observational studies and
indirect evidence analysis of pre-specified subgroup
of randomized clinical trials or meta-analysis with
low heterogeneity.
Level C
Evidence from small studies, non-randomized
or open
Level D Expert opinionSummary of evidence:
 The DCCT [1] and UKPDS [2,3] classic studies
conducted in subjects with type 1 and type
2 diabetes have demonstrated convincingly that
intensive glycemic control (HbA1c ~ 7.0%) reduces
chronic microvascular complications [4] and,
in the long- term, can also reduce the occurrence of
non-fatal acute myocardial infarction [5,6]. Evidence
from 3 large clinical trials in patients with type 2
diabetes - ADVANCE [7], ACCORD [8] and VADT
[9], which evaluated more-intensive compared to
less- intensive glycemic targets, showed only reduced
microvascular, but not macrovascular complications.
Meta-analysis that included these studies showed
marginal reduction in the risk of myocardial
infarction with more intensive glycemic control, but
with an increase in the number of severe
hypoglycemias [10]. Thus, the target for the
treatment of hyperglycemia in type 2 diabetes is to
achieve A1C levels of ~ 7%, and specific glycemic
goals are: fasting glucose between 70–130 mg/dL
and postprandial glucose <180 mg/dL [11].
2. In elderly patients with co-morbidities that
significantly limit life expectancy, in whom the
risk of hypoglycemia is even more harmful, it is
acceptable to seek an A1C target level of up to
7.9%. [Level B]
Summary of evidence:
 Less stringent target (A1C 7.0 to 7.9%) should be
considered in patients with a history of frequent
episodes of hypoglycemia, late-onset diabetes, micro
or macrovascular advanced disease or when there is
difficulty in maintaining good glycemic control,
despite the association of various medicines. In
ACCORD [8] study, although there was a reduction
in cardiovascular morbidity, there was also an
increase in mortality with more intensive control. A
meta-analysis showed only marginal reduction in the
risk of myocardial infarction with intensive glucose
control, but with an increase in the number of severe
hypoglycemia [10]. Data from observational studies
also reinforce the need to target A1C to less stringent
levels, showing that the lowest risk of mortality
occurs around an A1C of 7.5% [12]. The absolute
benefit obtained with intensive treatments in 5 years
is modest: the number needed to treat (NNT) to
prevent one event is 140 for ischemic heart disease,
768 for stroke, 272 for mono-ocular blindness and
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(NNH) is 328 for total mortality and 21 for severe
hypoglycemia [10,13]. Furthermore, the maintenance
of A1C from values below 8% is also less
cost-effective [14].
3. In patients hospitalized for acute myocardial
infarction (AMI), it is suggested to maintain
blood glucose between 130 and 180–200 mg/dL
using continuous intravenous insulin. [LEVEL B]
Summary of evidence:
 Three randomized clinical trials have evaluated
the role of glycemic control in the incidence of
cardiovascular events after an acute myocardial
infarction (AMI) in patients with diabetes. The
first was the DIGAMI [15] study, in which 620
patients with DM and AMI were included.
Treatment strategies were: infusion of insulin and
glucose IV in the first 24 hours with a glycemic
target of 126–196 mg/dL, followed by
subcutaneous administration of insulin four times
daily for 3 months vs. insulin therapy only when
clinically indicated. The group using insulin in the
acute phase had better glycemic control during
hospitalizationat 3 months and at 1 year, and
also had lower mortality rates at 1 and 3.4 years
of follow-up.
 The DIGAMI-2 [16] compared 3 groups: insulin
during hospitalization followed by outpatient use,
use of insulin only during hospitalization and
usual treatment throughout the period. Glycemic
control was similar between groups as well as
cardiovascular outcomes.
 HI-5 [17] study included 240 patients with a
history of diabetes and glucose ≥ 140 mg/dL on
hospital admission for AMI, who were randomized
to strict glycemic control (target 72–180 mg/dL)
with insulin plus intravenous glucose infusion for
at least 24 hours or conventional therapy.
Subsequently, patients were managed by their
physician, with a recommendation to maintain
A1C < 7%. The rates of in-hospital mortality did
not differ between groups.
4. In patients in the immediate postoperative
cardiac surgery, it is recommended to maintain
blood glucose between 120 and 150 mg/dL using
continuous intravenous insulin. [LEVEL A]Summary of evidence:
 Hyperglycemia before or after cardiac surgery is
associated with a higher risk of complications such
as death, prolonged mechanical ventilation, renal
failure, stroke and deep sternal infection [18,19].
 The Portland Diabetes Project was an
observational study that evaluated the relationship
between hyperglycemia and adverse outcomes of
cardiac surgery in patients with diabetes. It
consisted of using continuous intravenous insulin,
adjusted by frequent blood glucose tests based on
standardized protocol conducted by nurses,
with target glycemia 150–200 mg/dL.
Subsequently, this blood glucose target has
changed to 125–175 mg/dL and then to 100 to
150 mg/dL, because studies in other scenarios
were identifying the need for normalization of
blood glucose reduction outcomes. The use of this
protocol compared with the use of subcutaneous
insulin according to glucose levels (historical
control) was associated with reduced rates of
infection [20] and death in about 50% [21].
 A randomized clinical trial with patients in the
surgical intensive coronary unit (ICU), (mostly in
post-cardiac surgery (63%) and 13% with diabetes)
showed benefit with intensive glycemic control
(insulin infusion for glycemic target 80–110 mg/dL
vs. 180–200 mg/dL) in mortality, infection,
acute renal failure with hemodialysis, blood
transfusion, and polyneuropathy in critically ill
patients, but at the expense of higher rates of
hypoglycemia [22].
 However, multicenter clinical trial with larger
number of patients (Nice Sugar Study) conducted
in medical and surgical ICUs (63% and 37% of
patients, respectively), 20% with a history of
diabetes, showed that intensive glycemic control
(target <108 mg/dL) vs. usual control (140 to
180 mg/dL) resulted in increased mortality and
also higher rates of hypoglycemia [23].
 Meta-analysis including data from NICE SUGAR
study, evaluating separately results obtained from
clinical and surgical ICUs, showed that tight
glucose control offers no reduction of mortality in
patients in clinical ICU, but may have benefit in
surgical patients when target blood glucose is
below 150 mg/dL [24]. In a small randomized
clinical trial comparing two recent glycemic targets
(90–120 mg/dL vs. 120–180 mg/dL) in patients
with diabetes undergoing coronary artery bypass
grafting, a more stricted blood glucose control
provided no benefit and even increased the risk of
hypoglycemia [25].
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of coronary artery disease
5. It is recommended that patients with type 2
diabetes without a history of cardiovascular
disease have their cardiovascular risk stratified
annually by the UKPDS risk-calculator, using
the outcome: (CHD - Coronary Heart Disease)
in 10 years. Through this tool, patients should
be divided into low risk (<10% in 10 years),
intermediate risk (10-20% in 10 years) and
high risk (>20% in 10 years). [LEVEL D]
Summary of evidence:
 The UKPDS calculator was validated from a
multiethnic population of the United Kingdom,
originating from the UKPDS study, with 4,540
participants with type 2 diabetes between 25–65
years of age without a prior history of
myocardial infarction, angina or heart failure
[26]. The calculator has its best performance in
the range of intermediate risk, with low levels of
underestimation (13%), being higher than the
overall risk scores developed for the generalFigure 1 Example of calculating cardiovascular risk with the use of apopulation like the Framingham score, if applied
to a population with diabetes [27].
Figure 1 shows the screen of the UKPDS calculator
for the assessment of cardiovascular risk, taking into
account the following parameters: age, duration of
diabetes, sex, presence or absence of atrial fibrillation,
ethnicity, presence or absence of smoking, A1C level,
systolic blood pressure, total cholesterol and HDL
cholesterol. With the inclusion of these data by the
operator, this tool calculates the 10-year risk of occur-
rence of fatal and nonfatal CHD and fatal and nonfa-
tal stroke (Figure 1).
This calculator can be downloaded without charge
from the following address:
http://www.dtu.ox.ac.uk/riskengine/download.php
6. In patients with diabetes and cardiovascular
risk assessed as an intermediary by the
UKPDS calculator, we suggest performing
the evaluation of coronary calcium score
(CAC) in order to reclassify to low risk when
the score is less than 10 or intermediate/high
risk when more than 10, when available.
[LEVEL A]UKPDS calculator, considering the parameters provided.
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 The coronary artery score (CAC) proved to be a
good identifier of low-risk sub-population of
patients with diabetes. A meta-analysis of 8
observational studies in 6,521 patients with
diabetes with a mean follow-up of 5.2 years,
comparing CAC <10 vs. >10, showed a relative
risk of death from all causes or cardiovascular
events in the group >10, 5.47 times higher
(95% CI 2.59 to 11.53). For patients with
CAC < 10, post-test probability of a primary
endpoint was 1.8%, representing a reduction of 6.6
times from the pre-test probability. The CAC <10
result was present in 28.5% of patients with
diabetes. Given the global prevalence of diabetes of
346 million, these data suggest that 86.5 million
people with diabetes may have low cardiovascular
risk [28]. A re-analysis of Jupiter and the MESA
study [29] showed that in the general population,
CAC = 0 corresponds to a cardiovascular event rate
of 0.8 per 1000 person-years.
7. It is recommended to conduct an annual
electrocardiogram for screening of coronary
heart disease in patients with type 2 diabetes.
[LEVEL D]
8. In asymptomatic diabetic patients under
75 years old, without rest ECG abnormalities
and without previous positive stress testing, it is
recommended not to perform universal screening
tests for coronary disease with induction of
myocardial ischemia. [LEVEL A]
Summary of evidence:
 The Detection of Ischemia in Asymptomatic
Diabetics (DIAD) [30] evaluated 1,123 participants
with type 2 diabetes without symptoms of coronary
artery disease, randomized to screening with
induction of ischemia test (myocardial perfusion
adenosine stress (n = 562) or no screening (n = 561).
Patients with evidence of cardiovascular disease or
changes in the resting electrocardiogram were
excluded from the protocol. Patients with a mean age
of 61 years, duration of diabetes > 8 years and mean
A1C of 7.1% were included. The cumulative rate of
cardiac events (nonfatal myocardial infarction and
cardiovascular death) was lower than expected,
occurring in 2.9% of patients in the follow-up of
4.8 years. In total, only 15 cardiac events occurred
among the screened patients and 17 among non-
screened (OR 0.88, 95% CI 0.44 to 1.88, p = 0.73).While screening has not implicated in a
significant difference in clinical outcomes, patients
with moderate to large myocardial perfusion
defects had higher rates of cardiac events (OR
6.3, 95% CI 1.9 to 20.1, p = 0.001). A sub-analysis
of 5 years following this same study [31] has
suggested that the majority of enrolled patients
were classified as intermediate or high
cardiovascular risk. However, the annual risk of
cardiac events in these patients remained low
and was not altered by the strategy of screening
for inducible ischemia, so the conclusion is that
the screening of myocardial ischemia does not
reduce the rate of cardiac events in patients
with asymptomatic diabetes.
9. It is recommended to assess myocardial
ischemia in patients with cardiovascular
symptoms or with evidence of atherosclerotic
disease in other vascular sites (peripheral
vascular disease, carotid bruit, transient
ischemic stroke or previous episodes, or
presence of Q waves on resting ECG).
[LEVEL D]
10. The treadmill stress test is recommended as
initial test for most patients who present
indication for the investigation, excepting
those who are unable to walk, those with
resting ECG showing changes that hinder
the interpretation of the test, or those
with contraindications for the test.
[LEVEL D]
Module 3: treatment of dyslipidemia
11. Patients with diabetes and a prior history
of cardiovascular events (myocardial
infarction, stroke, coronary revascularization,
atherosclerotic disease of carotid, renal or
peripheral arteries and the aorta) should
begin intensive treatment with statins.
[LEVEL A]
Summary of evidence:
 Statins have proven to reduce the risk of
cardiovascular events in patients with diabetes
and a previous history of vascular events. A
meta-analysis of 14 trials including 18,686
patients with diabetes showed that treatment
with statins reduces proportionately the
incidence of vascular events by 20% for each
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reductions are similar for major coronary events,
stroke and need for revascularization [32].12. In patients with diabetes and confirmed
cardiovascular disease, it is recommended to
reduce LDL-c at least 50% of the baseline
values with statins at the highest tolerated
doses. Alternatively it is reasonable to reduce
LDL-c below 70 mg/dL with statins. [LEVEL B]
Summary of evidence:
 A comparison between intensive vs moderate statin
treatment was evaluated in a meta-analysis of 5
randomized trials with 39,612 individuals, where
5,639 (19%) had diabetes, and 59% had prior
vascular disease, with a mean follow-up of 5.1 years
[33]. Intensive treatment was defined as a reduction
of 20 mg/dL LDL-c beyond the result obtained by
moderate treatment with the use of higher power
statins. The results showed 15% reduction in major
vascular events (95% CI 11–18, p < 0.0001), 13% in
coronary death (95% CI 7–19, p < 0.0001), 19% in
coronary artery myocardial (95% CI 15–24
p < 0.0001) and 16% in stroke (95% CI 5–26,
p = 0.005). Intensive treatment promoted a 20%
reduction in LDL-c beyond the moderate treatment,
while the moderate treatment promoted a decrease of
30% compared to placebo. Thus, there was an overall
50% reduction in events with intensive treatment
compared to placebo. Although this is an indirect
evidence, based in subgroup analysis of diabetic
patients included in the meta-analysis, the absence of
heterogeneity makes it plausible to be applied to
patients with DM in secondary prevention.
 A pre-specified subgroup analysis of the Treat to
New Targets (TNT) study, which included
1,501 patients with diabetes and coronary artery
disease [34], compared the treatment with
atorvastatin 80 mg vs. atorvastatin 10 mg for
4.9 years in cardiovascular outcomes. The study
showed a significant reduction in any
cardiovascular events and strokes in patients
with a dose of 80 mg. Patients taking 10 mg
maintained an average level of LDL-c of
96 mg/dL, while those using 80 mg/day reached
77 mg/dL. Thus, the use of a target LDL-c
around 70 mg/dL showed additional benefit. This
committee considered that obtaining the target of
70 mg/dL is quite similar to a 50% reduction in
baseline LDL-C in the great majority of cases, and
therefore may alternatively be used as a target to
facilitate treatment adherence.13. It is recommended that patients with LDL-c >
190 mg/dL receive statin treatment regardless of
having or not a previous cardiovascular event,
with the goal of a 50% reduction in cholesterol
levels. [LEVEL D]
Summary of evidence:
 Although most of the clinical trials do not include
patients with LDL above 190 mg/dL, indirect
evidence from several clinical trials shows that every
39 mg/dL reduction in LDL-c produces a reduction
of 20% in the risk of events related to cardiovascular
atherosclerotic disease [35]. This positioning is in
accordance to the ACC/AHA 2013 guidelines that
recommends to use statins due to the high
probability of associated familial
hypercholesterolemia [36].
14. It is recommended that dialysis patients do not
initiate the use of statins for lack of evidence of
benefit in this population, with possible increase
in risk of stroke. However, it is recommended not
to withdraw the statin in patients with chronic
renal failure who are already in use of statin
before initiation of dialysis. [LEVEL A]
Summary of evidence:
 The 4D study [37] evaluated 1,255 patients with type
2 diabetes on hemodialysis that were randomized to
atorvastatin 20 mg or placebo and followed up for
4 years. The primary endpoint was a composite of
death from cardiac causes, nonfatal myocardial
infarction, and stroke. There was a 42% reduction in
LDL-c in patients using atorvastatin, however there
was no reduction in the primary outcome, and yet it
increased the risk of stroke in this group.
 The AURORA study [38] was a randomized,
multicenter trial which included 2,776 hemodialysis
patients, with ages between 50–80 years, being 27.9%
with diabetes which were treated with rosuvastatin
10 mg/day or placebo during a mean of 3.8 years.
The evaluated primary outcome was a composite of
nonfatal myocardial infarction, nonfatal stroke, and
cardiovascular death. Even with a 43% reduction in
LDL-c in the intervention group, no differences in the
primary outcome were observed between groups.
 In respect of patients with chronic renal disease but
not in hemodialysis, an analysis of the database of
Pravastatin Pooling Project combined results of 3
randomized trials using pravastatin 40 mg vs.
placebo [39] including 19,700 patients with chronic
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This analysis showed significant benefit of treatment
in reducing the primary end point of myocardial
infarction, coronary death or percutaneous
revascularization and total mortality in this
particular group of patients. In light of these
findings, there are potential benefits for the use of
statins in patients in pre-dialysis, so that the present
positioning recommends not to remove the statin in
patients who were already in use of statin prior to
the start of hemodialysis.
15. It is recommended that patients with heart
failure class II to IV do not initiate statin
therapy because there is no clear evidence of
benefit in this group. [LEVEL A]
Summary of evidence:
 The randomized, multicenter clinical trial
(GISSI-HF) evaluated rosuvastatin 10 mg/day
compared to placebo, in 2,285 patients with heart
failure at classes II to IV (New York Heart
Association), including 26% of patients with diabetes.
There was no benefit over the outcomes: death and
hospitalization for cardiovascular causes [40].
 The randomized CORONA study, with 5,011
patients over 60 years showing heart failure class II
to IV, where 29% had diabetes, compared the use of
rosuvastatin 10 mg versus placebo, assessing the
primary endpoint composed of cardiovascular death,
acute non-fatal MI and non-fatal stroke during
36 months. Even reducing LDL-c in 45% there was
no significant difference between the groups regarding
the primary outcome. The results were extensive to
patients with diabetes in the subgroup analysis due
to low heterogeneity [41].
16. Patients with type 2 diabetes without a history
of cardiovascular events, aged 40–75 years, with
1 or more risk factors (hypertension, retinopathy,
micro or macroalbuminuria, smoking or family
history of coronary heart disease) should start
treatment with statins. [LEVEL A]
Summary of evidence:
 In CARDS study [42], 2,838 patients with diabetes
without coronary artery disease prior to age 40
and 75 years and at least 1 additional risk factor
(microalbuminuria, retinopathy, hypertension or
smoking) were randomized to atorvastatin 10 mgor placebo during a mean follow-up of 3.9 years.
The primary outcome was a composite of acute
coronary events, coronary revascularization or
stroke. The study was terminated prematurely
due to efficacy. Atorvastatin 10 mg promoted risk
reduction of 37% (95% CI −52 to −17, p = 0.001)
in the primary endpoint, a reduction of 32%
(95% CI −45 to −15, p = 0.001) in the risk stroke
and a trend of 27% reduction in total mortality
(95% CI −48 to 1,0 p = 0.059). By this study it is
estimated that one event is avoided for every
27 patients treated for 4 years.
 The HPS (MRC/BHF Heart Protection Study)
substudy [43] randomized 5,963 individuals with
diabetes aged 40–80 years, to receive simvastatin
40 mg or placebo. Prespecified subgroup analysis
was performed for the outcomes of fatal and
non-fatal acute myocardial iInfarction (AMI) and
the first vascular event (major coronary event,
stroke, or revascularization). Simvastatin 40 mg
reduced these outcomes in 33% (95% CI 17–46,
p < 0.0003), regardless of the level of baseline
LDL-c. The absolute risk reduction of
cardiovascular disease in patients with diabetes
without coronary artery disease in HPS was very
similar to the CARDS study, confirming the
benefit of statins in patients with diabetes in
primary prevention in the high-risk group.
17. Treatment with statins is recommended in
patients with cardiovascular risk classified as
intermediate or high risk by UKPDS risk engine.
[LEVEL B]
Summary of evidence:
 A meta-analysis of 22 randomized controlled trials
evaluated 134,537 subjects at low cardiovascular
risk comparing treatment with statins against
placebo or less intensive statin therapy for 4.8 years
who were subdivided into strata of cardiovascular
risk. In stratum 10-20%/10 years, there were 18%
of patients with diabetes. There was a 21%
reduction in major vascular events for each
39 mg/dL reduction in LDL-c, regardless of age,
gender, baseline LDL-c or presence of previous
vascular disease. Considering patients without
prior vascular disease with risk between 10-20% in
10 years, there was a 34% reduction in major
vascular events for each mmol reduction in LDL-c
in 5 years, with no increase in cancer incidence or
mortality from other causes. It is estimated that
15 adverse events could be avoided for each
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treated for 5 years. The benefit was greater than
the incidence of adverse events, even in diabetes
patients [44].18. This Position Statement did not find evidences
to support the recommendation for treating
to LDL-c target of LDL-c < 100 mg/dL in
patients with diabetes without established
cardiovascular disease.
After an extensive review, this board did not find any
randomized clinical trial indicating that a titrated drug
therapy to a specific LDL-c goal does improve cardiovas-
cular outcomes in diabetic subjects. This recommenda-
tion is in accordance to the 2013 ACC/AHA guideline on
the treatment of blood cholesterol to reduce atheroscler-
otic cardiovascular risk in adults [36]. Although the
American Diabetes Association 2014 position statement
still suggests the use of LDL-c targets for patients with dia-
betes, they also recommend a relative reduction LDL-c of
30-40% from baseline as an alternative effective goal [45].
The present Position Statement agrees that the use of
LDL-c target of 100 mg/dl may result in under-treatment
with statins which have a large body of evidence of event
reduction or even overtreatment with non-statin drugs
that have no evidence in reducing cardiovascular out-
comes despite LDL-c reduction.
19. In patients with intermediate coronary heart
risk (10-20% in 10 years) the calcium score
(CAC) can be determined, if available. Patients
with CAC scores below 10 may be considered
of low cardiovascular risk and should be
oriented about changes in lifestyle (healthy
diet, weight loss if overweight or obesity and
physical activity). Patients with calcium score
greater than 10 are considered CAC
intermediate-high risk and should be treated
with statins. [LEVEL A]
Summary of evidence:
 Meta-analysis of 8 studies [28] including 6,521
patients with diabetes and 5.2 years of follow-up
compared mortality and vascular events according
to calcium score. Mortality from all causes in
patients with CAC score <10 compared to patients
with CAC score > 10 was 5.47 times lower
(95% CI 2.59 to 11.53, p < 0.001). For patients
with CAC score <10, the post-test probability of
primary outcome was 1.8%, representing a
reduction of 6.8x compared to pre-test probability.
The risk of cardiovascular events in patients witha CAC score <10 was 9.22 (95% 2.73 to 31.07
p = 0.005). The prevalence of patients with
CAC score <10 was 28.5%. Patients with
CAC score above 10 have cardiovascular risk of
3% per year and are considered intermediate to
high risk [28].
20. Patients with diabetes and low cardiovascular
risk (CHD <10% in 10 years) may receive only
treatment with changes in lifestyle (healthy diet,
weight loss if overweight/obesity and physical
activity), however the coronary risk should be
re-evaluated yearly. [LEVEL B]
Summary of evidence:
 In the same meta-analysis mentioned in the previous
recommendation [28], 24,790 patients were classified
as low cardiovascular risk and 7% had diabetes. In
this group, the benefit found was a reduction in 6
major cardiovascular events per 1000 patients treated
for 5 years for each reduction of 39 mg/dL LDL-c. By
the data of this metanalysis, only 1,2-vascular deaths
for every 1000 patients treated with statins for 5 years
could be avoided with a reduction of LDL-c of
39 mg/dL. This Position Statement held that, although
there was no increase in adverse events in 5 years, the
benefits are too faint for a systematic indication of sta-
tin for this stratum of risk and a clear isk-benefit study
is still needed. This position, however, reiterates the
need for annual review of risk stratification for possible
re-classification.
21. Association between statin and fibrate is not
usually recommended for patients with diabetes
to reduce cardiovascular risk. However, in the
specific situation of men with triglycerides above
204 mg/dL in association with HDL-c below
34 mg/dL, the combination fenofibrate-statin
may be considered. [LEVEL B]
Summary of evidence:
 This is a recommendation based on the analysis
of pre-specified subgroup analysis of patients with
diabetes from the ACCORD-LIPID study [46],
comparing the fenofibrate-simvastatin combination
versus simvastatin alone whose trial showed no
reduction in the primary outcome. As there was
benefit in prespecified subgroup analysis of men
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less than 34 mg/dL, this committee considers that
the information is still preliminary and should be
viewed with caution.
Algorithm SBD-2014 for the use of statins in patients with
diabetes
Based on the currently available literature and after careful
review of national and international recommendations by
the Expert Group on Diabetes and Cardiovascular Risk of
the Brazilian Diabetes Society (SBD), the following algo-
rithm for suggested criteria for statin therapy in patients
with diabetes was developed (Figure 2).
Module 4: hypertension
22. Patients with blood pressure levels greater than
or equal to 140/90 mmHg should be considered
hypertensive. Patients with levels close to these
limits, with no evidence of organ damage, should
be reevaluated periodically. It is recommended to
measure blood pressure at each routine visit.
[LEVEL A]
Summary of evidence:
 A meta-analysis of 61 observational studies [47]
showed that, in the range of 40–69 years old,Figure 2 Decision making flow for statin use.each increment of 20 mmHg systolic and
10 mmHg diastolic, is associated to a 2-fold
increase in incidence in death from stroke and
coronary ischemia. Blood pressure above
115/75 mmHg is associated with an increased
risk for cardiovascular events, mortality
and end stage renal disease in patients with
diabetes [47].23. It is recommended that patients with systolic
blood pressure between 120–139 mmHg or
diastolic pressure between 80–90 mmHg should
be treated with non-pharmacological measures
to control blood pressure. [LEVEL C]
Summary of evidence:
 Because there is no clear evidence of benefit from
pharmacological treatment with systolic blood
pressure below 140 mmHg, only recommended
lifestyle modifications are indicated. A randomized
clinical trial including 412 subjects [48] compared
diets with high, medium and low sodium during 30
consecutive days. The DASH diet (low sodium)
resulted in a reduction in average systolic blood
pressure of 7.1 mmHg compared to the control diet
in individuals without hypertension and of
11.5 mmHg in hypertensive individuals. The diet,
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diabetes. Although there are no well-controlled study
in the treatment of hypertension with diet and
exercise in patients with diabetes studies, the
DASH study group showed similar effects with
pharmacological treatment in other studies, with
results accepted for patients with diabetes, since the
risk of adverse effects is negligible. It is recommended
that sodium intake should be kept at less than
1,500 mg/day. Excess weight should be controlled.
The use of low-fat dairy products, 2–3 daily servings
of fruits and vegetables, limited alcohol intake and
regular physical activity should be advised.
24. It is recommended that patients with
hypertension defined as systolic blood pressure
equal to or greater than 140 mmHg or diastolic
blood pressure greater than or equal to 90 mmHg
receive pharmacological treatment. [LEVEL A]
Summary of evidence:
 A meta-analysis of 31 randomized controlled trials
with 73,913 patients with diabetes [49] compared the
effect of antihypertensive treatment regimens defined
as intensive or less intensive in outcomes such as
myocardial infarction and stroke. The meta-analysis
found that risk-reductions for stroke and MI are
firmly established when comparing antihypertensive
agents against placebo. However, when comparing
more intensive with less intensive regimen, there was
no additional benefit, except a reduction in stroke.
Protection is progressive for stroke, but not for acute
myocardial infarction. However, no increased
incidence of AMI is observed with more intensive
blood pressure reductions, suggesting that reductions
below to around 130 mmHg, can be safely pursued.
25. It is recommended to reduce systolic pressure to
below 140 mmHg and diastolic pressure to
around 80 mmHg, regardless of the presence
of micro or macrovascular complications.
[LEVEL A]
Summary of evidence:
 The ACCORD BP study [50] was a non-blind arm
of the ACCORD trial that directly compared the
antihypertensive treatment goals with systolic BP
<120 mmHg vs. Systolic BP <140 mmHg in 4,733
patients with type 2 diabetes at high cardiovascular
risk, with follow-up of 4.7 years. The mean systolicBP was 119.3 mmHg in the intensive group and
133.5 mmHg in the conventional group. The primary
composite outcome (nonfatal MI, nonfatal stroke,
and cardiovascular death) was not different between
groups. In prespecified secondary outcome, the
incidence of stroke was lower in the intensive group
(p <0.001). However, the intensive group had a
higher rate of adverse effects such as hypotension,
hypokalemia, and increased creatinine. Thus, in
high-risk patients, it is recommended to reduce sys-
tolic BP below 140 mmHg but not below 120 mmHg
due to the increased risk of adverse effects.
 A meta-analysis of 5 trials, both observational and
randomized clinical trial, including 7,312 patients
with diabetes showed that intensive treatment with a
reduction in systolic BP to below 130 mmHg vs.
reduction of systolic BP to below 140 mmHg showed
reduction of the risk of stroke but not in mortality or
in acute myocardial infarction [51].
26. Due to the similarity of benefit in cardiovascular
outcomes, it is recommended that the decision in
the choice of initial drug therapy, including the
major classes of antihypertensive drugs, is based
on tolerability, cost, and presence of comorbidities.
Regarding renal protection, ACE inhibitors and
angiotensin receptor blockers are superior.
[LEVEL A]
Summary of evidence:
 A meta-analysis of 27 randomized trials with
158,709 patients including 33,395 patients with
diabetes, the options of diuretics, calcium
dihydropyridine blockers, ACE inhibitors and
angiotensin II receptor blockers (ARBs) were equally
effective in reducing cardiovascular events in subjects
with or without diabetes [52].
 A meta-analysis including 63 randomized controlled
trials with 36,917 patients with diabetes compared
different antihypertensive drugs versus placebo [53].
ACE inhibitors have consistently shown higher
probability in being superior compared to other
antihypertensive drugs in relation to renal outcomes,
mortality from all causes, onset of dialysis or
doubling of creatinine. The meta-analysis also
demonstrated superiority of ACE inhibitors in
relation to reno-protection, with similar benefit
when ARBs are used.
27. In the need of using more than one
antihypertensive to achieve target blood pressure,
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between an angiotensin converting enzyme
inhibitor with a dihydropiridin calcium blocker.
[LEVEL A]
Summary of evidence:
 The randomized ACCOMPLISH trial [54]
included 11,506 patients with high blood pressure
and with cardiovascular high risk, including 60%
of patients with diabetes. These patients were
randomly assigned to associations to receive
benazepril plus amlodipine or benazepril plus
hydrochlorothiazide for 36 months. The study
showed that the combination benazepril plus
amlodipine is superior to the combination of
benazepril plus hydrochlorothiazide in reducing
the risk of cardiovascular events and mortality
(reduction of relative risk of 19.6% p <0.001).
Subgroup analysis showed that patients with
diabetes had similar benefits as the non diabetic
patients.
 In a meta-analysis comparing various strategies
for antihypertensive treatment including 36,917
patients with diabetes, a total of 640 (1.7%)
patients received combination ACEI-calcium
blocker. The combination of ACEI- Calcium
Channel Blocker was shown to have the most
significant effect in reducing mortality compared
to other combinations [53].
28.The use of ACE inhibitors or ARBs in patients
with micro or macroalbuminuria is
recommended. [LEVEL A]
Summary of evidence:
 In diabetic patients with macroalbuminuria the
RENAAL study [55] showed efficacy of losartan
compared to placebo in reducing renal outcomes as
doubling creatinine, end- stage renal disease or
death. Likewise, the IDNT study [56] demonstrated
superiority of irbesartan compared to amlodipine in
the reduction of the same renal endpoints.
 In patients with microalbuminuria the IRMA-2
study [57] showed progressive reduction of
albuminuria with increasing doses of irbesartan.
29. It is recommended to AVOID the combination of
ACE inhibitors with ARBs due to greater risk of
loss of renal function and hyperkalemia.
[LEVEL A]Summary of evidence:
 The ONTARGET study [58] evaluated the effects of
adding an ACE inhibitor (ramipril) to an ARB
(telmisartan) in 25,620 patients over 55 years,
high-risk, including 9,603 with diabetes during
56 months. Participants were randomized into 3
groups: ramipril, telmisartan and a combination of
ramipril with telmisartan. The primary renal
outcome was a composite of dialysis, doubling of
creatinine and death. The primary outcome was
worse with the combination ramipril-telmisartan
than with each of antihypertensive monotherapy
(HR 1.09 95% CI: 1.01-1.18 p = 0.037). Thus, the
ACEI-ARB combination since is contra-indicated due
to its association with worsening of renal outcomes.
30. In pursuit of the goals of blood pressure, other
options of combination of 3 or more drugs may
be considered, depending on clinical criteria,
including ACEI or ARB with amlodipine,
thiazide diuretics, beta-blockers, spironolactone,
and vasodilators, but with a lower level of
evidence. [LEVEL D]
Module 5: antiplatelet therapy
31. The use of acetylsalicylic acid (ASA)
(75–162 mg/day) for coronary risk reduction
in patients with diabetes and previous
cardiovascular events is recommended.
[LEVEL A]
Summary of evidence:
 Meta-analysis of the Antithrombotic Trialists (ATT)
Collaboration [59] showed that in secondary
prevention trials, aspirin compared to placebo
resulted in significant reduction of major vascular
events (6.7% vs 8.2% per year, p < 0,0001), with no
increase in the risk of hemorrhagic stroke, but
significant reduction in total stroke (2.08% vs 2.54%
per year, p = 0.002) and coronary events (4.3% vs
5.3% per year p < 0.0001).
 The use of ASA for secondary cardiovascular
prevention was associated with a significant
reduction in mortality in a meta-analysis of 13 stud-
ies involving diabetic patients (RR: 0.82, 95% CI: 0.69
to 0.98, p = 0.03) [60].
32. In patients with diabetes without a history of
cardiovascular events (primary prevention) ASA
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patients (>20% in 10 years). For patients at
low or moderate risk, ASA use is not usually
recommended since the risk of significant
gastrointestinal bleeding may outweight the
cardiovascular benefit. [LEVEL A]
Summary of evidence:
 The effect of ASA was reported in only 2 large
studies with diabetic patients. The POPADAD
study [60] evaluated 176 patients with age above
40 years, with both DM1 and DM2, without prior
cardiovascular disease. Patients were randomized
to receive ASA 100 mg, antioxidant, antioxidant
plus ASA or placebo for 5 years. There was no
difference in the primary outcome between the
groups.
 In the second study, JPAD study [61], researchers
examined the efficacy of aspirin in primary
prevention in an open study in 2,539 Japanese
individuals with diabetes without a history of
cardiovascular disease. Patients were randomized
to ASA or nothing and were followed for
4.4 years. There was no difference in the total
number of events between the group receiving
ASA and those who did not receive it (HR 0.80
95% 0.58 to 1.10). The secondary outcome of
coronary and cerebrovascular mortality however,
was favorable to the ASA group (HR 0.10 95%
0.01 to 0.79).
 A meta-analysis by the Trialists (ATT) [59]
including 6 large studies with ASA in primary
prevention in the general population including
95,000 individuals and 4,000 with diabetes,
showed that ASA reduces by 12% (RR 0.88, 95%
0.82 to 0.94) the risk of vascular events, with the
largest reduction for nonfatal MI, with little effect
on coronary death and a relative increase in the
risk of hemorrhagic stroke (32%). The effect was
similar in the subgroup of patients with diabetes.
 In another meta-analysis [62] only with diabetic
patients, including POPADAD and JPAD
studies, showed that ASA was associated with
non-significant 9% reduction in risk of coronary
events and 10% in stroke.
 A meta-analysis that evaluated the use of
low-dose aspirin in 9 studies (observational and
randomized clinical trials) in 11,787 diabetic
patients also showed no significant benefit
(9% reduction) in relation to coronary events
(95% CI 0.79 - 1.05) as compared to AVC
(non-significant reduction of 10% (95% CI 0.71-
1.13) [63]. Similar results were found in 2 othermeta-analysis [64,65]. In another meta-analysis
in general population [64], ASA reduced risk of
MI only in men (relative risk, 0.57 [95% CI 0.34
to 0.94]).
 The absolute risk of hemorrhagic stroke with
low-dose aspirin in the general population is
1:10,000 people annually [66]. In relation to
gastro-intestinal bleeding, the absolute risk of
gastrointestinal bleeding with aspirin in
middle-aged adults is 3 per 1000 per year [63].
Patients with diabetes have a relative increase
of 55% in the risk of bleeding (95% CI 1.113 to
2.14) compared to patients without diabetes,
observed in meta-analysis of 6 studies by
Trialists in primary prevention [59]. The
combined use of proton pump blockers can
reduce this risk [67].
33. In patients with defined cardiovascular disease
and documented allergy to ASA, clopidogrel may
be used. [LEVEL C]
Summary of evidence:
 The CAPRIE study [68] was a randomized
double-blind clinical trial that compared the
relative efficacy of clopidogrel 75 mg compared to
ASA 325 mg in reducing the primary composite
end point of ischemic stroke, myocardial infarction
or vascular death in patients with ischemic
stroke, r acute myocardial infarction and recent
peripheral vascular insufficiency for a follow-up of
1–3 years. There were 19,185 patients included
being 20% of diabetic patients. The study showed
superiority of clopidogrel compared with ASA in
preventing the primary outcome (Relative risk
reduction of 8.7% in favour of clopidogrel (95% CI
0.3-16.5) with a similar safety profile. Data for
diabetic patiets are indirect.
34. In patients with diabetes presenting with
acute coronary syndrome (ACS) it is
recommended the dual antiplatelet treatment
with aspirin associated with a P2Y12 receptor
antagonist for 1 year after the acute event. Data
from clinical trials indicate that the benefit is
greater with prasugrel and ticagrelor compared
to clopidogrel in the general population with
ACS. In a subgroup analysis of patients with
diabetes, prasugrel was superior to clopidogrel in
patients with ACS undergoing PCI.
[LEVEL B]
Bertoluci et al. Diabetology & Metabolic Syndrome 2014, 6:58 Page 13 of 18
http://www.dmsjournal.com/content/6/1/58Summary of evidence:
 The results of five randomized trials that compared
the combination of ASA plus of P2Y12 receptor
antagonist with ASA alone are consistent in showing
greater benefit in reducing cardiovascular outcomes
with the combination. The studies, however, were not
performed exclusively in patients with diabetes. Thus,
there is a limitation for the interpretation of
these results. However, this committee recommends
the use of this combination in patients with
diabetes. The evidence supports the use of
clopidogrel and ticagrelor when no percutaneous
coronary intervention (PCI) is performed, and
clopidogrel, prasugrel or ticagrelor when PCI is
performed [69-73].
 The TRITON-TIMI 38 study compared prasugrel
with clopidogrel in 13,608 patients using aspirin after
percutaneous intervention. A prespecified subgroup
analysis in 3,146 patients with diabetes showed
a reduction of 30% (HR 0.7 95% CI 0.58 to 0.85,
p < 0.001) in the primary endpoint with prasugrel
compared to clopidogrel. No significant interaction
effect between the treatment and the presence of
diabetes, indicating that the data can be extended to
diabetic patients [73]. As this is a result of a
substudy these results are yet to be confirmed for
patients with diabetes.
Module 6: myocardial revascularization
35. It is recommended to consider coronary artery
bypass graft (CABG) in the following situations
[LEVEL B]:
– Myocardial ischemia symptoms not controlled by
medical treatment.
– Suspected extensive myocardial ischemia.
– Suspected ischemia with left ventricular
dysfunction and myocardial viability.
– Obstruction of greater than 50% in the left main
coronary artery.
Summary of evidence:
 The objectives of myocardial revascularization
(MR) are to reduce long-term mortality and
improve symptoms and quality of life in patients
not well controlled with optimal medical therapy.
Patients with diabetes and coronary artery disease
have higher long-term mortality compared to
patients without diabetes, regardless of treatment
strategy [74]. Just as for patients withoutdiabetes, the best criterion for decision MR in
patients with diabetes is the clinical assessment,
considering the presence of myocardial ischemia
(symptoms or evidence of complementary tests),
evaluation of coronary anatomy and left
ventricular systolic function. Indications for
MR in patients with diabetes are similar to
those for patients without diabetes, respecting
the existing guidelines [75-77].
36. Clinical treatment is recommended as the
initial strategy in cases of chronic stable
coronary artery disease with preserved
ventricular function, controlled symptoms,
evidence of myocardial ischemia and
coronary anatomy without high-risk criteria.
[LEVEL B]
Summary of evidence:
 The COURAGE study [78] randomized 2,287
patients with chronic CAD to receive optimal
medical therapy or angioplasty with stent associated
with clinical treatment. In the subgroup of 766
patients with diabetes there was no difference
between groups with respect to the combined
endpoint of mortality and nonfatal myocardial
infarction (HR: 0.99, 95% CI 0.73 to 1.32).
Importantly, patients with more severe angina
functional class IV (CCS IV), heart failure (HF),
ejection fraction (LVEF) <30%, recent myocardial
revascularization and evidence of ischemia at high
risk were excluded from the study.
 In BARI 2D study [79,80] authors randomized
2,368 patients with type 2 diabetes and chronic
coronary artery disease to initial strategy of
optimal medical therapy or medical treatment
with percutaneous or surgical revascularization.
There was no difference between groups in relation
to survival in a follow-up of 5 years (87.8% in
the medical therapy group vs. 88.3% in the
revascularized group, p = 0.97). However, in
patients undergoing surgical revascularization,
there was a lower rate of cardiovascular events
(death, MI, or stroke) compared to patients in the
clinical treatment (22.4% vs 30.5%, p = 0.01,
respectively). This study also excluded patients
with lesions of the left main coronary artery and
HF patients.
37. In patients with obstruction in more than one
arterial territory with indication for CABG,
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relation to angioplasty, provided that the
anatomy is favorable to the surgical procedure.
[LEVEL A]
Summary of evidence:
 The BARI study compared surgical Myocardial
Revascularization with balloon angioplasty in
patients with chronic coronary artery disease, and in
the subgroup of patients with diabetes, survival was
higher in the surgical group after a 5 to 10 years
follow-up [79,80].
 A meta-analysis using individual data from 7,812
patients showed a 30% reduction in mortality in the
subgroup of 1,233 patients with diabetes undergoing
CABG [81].
 The SYNTAX study subdivided the groups in relation
to the anatomical complexity, developing the
SYNTAX score [82]. On this score, patients with low
anatomical complexity (SYNTAX score ≤22) had the
same morbidity and mortality during follow-up.
However, in the subgroup of patients with
anatomically complex lesions (high SYNTAX score
≥33) showed a higher mortality with angioplasty
compared to surgery (13.5% vs 4.1%, p = 0.04,
respectively) [82]. In the 5 years follow-up these
patients confirmed the greater number of
cardiovascular events in the angioplasty group
(46.5% vs. 29%; p < 0.001) in patients with high
SYNTAX [83] score. In this analysis there was a
trend toward lower mortality in the CABG group,
but no statistically significant difference
(p = 0.065) [84].
 A subanalysis of the same study (SYNTAX) [82]
including 452 patients with diabetes, in which it was
compared surgery vs. stent angioplasty, patients
undergoing angioplasty with pharmacological stent
and lesion of the left main coronary artery or
three-vessel disease presented a higher rate of
cardiovascular events at one year than those who
underwent surgical revascularization (26% vs. 14.2%
respectively, p = 0.003).
 The FREEDOM study [85] randomized 1,900
patients with diabetes and at least bi-arterial lesions
(excluding injury in left main coronary artery trunk)
for surgical or percutaneous revascularization with
stent drug (sirolimus and paclitaxel). After five years
follow-up, patients who underwent surgery had
lower overall mortality (10.9 vs 16.3%; p = 0.049,
respectively) and lower incidence of AMI (6 vs. 13%,
9%, p < 0.001) than those who underwent
angioplasty. It should be emphasized that these
patients were not subdivided in relation to itsanatomical complexity [85]. Therefore, for
multi-arterial patients with indication for CABG,
surgery should be the preferred strategy in relation to
angioplasty, provided the anatomy is favorable to the
surgical procedure and the surgical risk be
acceptable.
38. In patients with diabetes and clinical indication
for percutaneous myocardial revascularization,
we suggest the use of pharmacological stent,
provided there is no contraindication to double
therapy of anti-platelet aggregation for a mini-
mum period of one year. [LEVEL B]
Summary of evidence:
 Patients with diabetes treated with drug-eluting
stents have a lower rate of need for repeat
revascularization than patients treated with
non-drug-eluting stents [86,87]. Following five
years of ARTS I and II studies [85,88], patients
with diabetes undergoing angioplasty with drug
eluting stents with sirolimus had a lower rate of
AMI and less need for revascularization than
patients who received non-pharmacological stent
(4,8% vs. 11%; 0.04 and p = 33.2% vs. 43.7%;
p = 0.02, respectively).
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